The Role of ctDNA in Gastric Cancer

doi:10.3390/cancers14205105

Review

. 2022 Oct 18;14(20):5105.

doi: 10.3390/cancers14205105.

The Role of ctDNA in Gastric Cancer

Justin Mencel¹, Susanna Slater¹, Elizabeth Cartwright¹, Naureen Starling¹

Affiliations

PMID: 36291888
PMCID: PMC9600786
DOI: 10.3390/cancers14205105

Review

The Role of ctDNA in Gastric Cancer

Justin Mencel et al. Cancers (Basel). 2022.

. 2022 Oct 18;14(20):5105.

doi: 10.3390/cancers14205105.

Authors

Justin Mencel¹, Susanna Slater¹, Elizabeth Cartwright¹, Naureen Starling¹

Affiliation

¹ Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation, London SW3 6JJ, UK.

PMID: 36291888
PMCID: PMC9600786
DOI: 10.3390/cancers14205105

Abstract

Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural genomic landscape compared to tissue-based next-generation DNA sequencing (NGS). In addition, ctDNA can potentially overcome the challenges of tumour heterogeneity seen with tissue-based NGS. Although the evidence for ctDNA in GC is evolving, its potential utility is far reaching and may shape the management of this disease in the future. This article will review the current and future applications of ctDNA in GC.

Keywords: ctDNA; gastric cancer; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

J.M., S.S., E.C., no conflict of interest; N.S., Advisory Board-Pfizer, AstraZeneca, Servier, MSD. Research funding-AstraZeneca, BMS, Pfizer. Honoraria-Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK, Amgen.

Cited by

The chemotactic response of Caenorhabditis elegans represents a promising tool for the early detection of cancer.
Kaiglová A, Hockicková P, Bárdyová Z, Reháková R, Melnikov K, Kucharíková S. Kaiglová A, et al. Discov Oncol. 2024 Dec 20;15(1):817. doi: 10.1007/s12672-024-01721-7. Discov Oncol. 2024. PMID: 39707061 Free PMC article.
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J, Reuther J, Scozzaro K, Hawley M, Metzger E, Emery M, Chen I, Barbosa M, Johnson L, O'Connor A, Washburn M, Hartje L, Reckase E, Johnson V, Zhang Y, Westheimer E, O'Callaghan W, Malani N, Chesh A, Moreau M, Daber R. Zhao J, et al. Mol Diagn Ther. 2023 Nov;27(6):753-768. doi: 10.1007/s40291-023-00670-1. Epub 2023 Aug 26. Mol Diagn Ther. 2023. PMID: 37632661 Free PMC article.
Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.
Han HS, Lee KW. Han HS, et al. J Gastric Cancer. 2024 Jan;24(1):4-28. doi: 10.5230/jgc.2024.24.e5. J Gastric Cancer. 2024. PMID: 38225764 Free PMC article. Review.
Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective single-centre clinical study.
Bai L, Guan Y, Zhang Y, Gu J, Ni B, Zhang HY, Aimaiti M, Wang S, Yue B, Xia X, Zhang Z. Bai L, et al. BMJ Open. 2024 Oct 1;14(10):e083659. doi: 10.1136/bmjopen-2023-083659. BMJ Open. 2024. PMID: 39353699 Free PMC article.
Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.
Ratti M, Orlandi E, Toscani I, Vecchia S, Anselmi E, Hahne JC, Ghidini M, Citterio C. Ratti M, et al. Cancers (Basel). 2024 Jul 29;16(15):2692. doi: 10.3390/cancers16152692. Cancers (Basel). 2024. PMID: 39123420 Free PMC article. Review.

See all "Cited by" articles

References

1. Rawla P., Barsouk A. Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Prz. Gastroenterol. 2019;14:26–38. doi: 10.5114/pg.2018.80001. - DOI - PMC - PubMed
1. Bernards N., Creemers G.J., Nieuwenhuijzen G.A.P., Bosscha K., Pruijt J.F.M., Lemmens V.E.P.P. No Improvement in Median Survival for Patients with Metastatic Gastric Cancer despite Increased Use of Chemotherapy. Ann. Oncol. 2013;24:3056–3060. doi: 10.1093/annonc/mdt401. - DOI - PubMed
1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
1. Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2022 doi: 10.1016/j.annonc.2022.07.004. - DOI - PubMed
1. Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Cooke D., Corvera C., Das P., Enzinger P.C., Enzler T., Fanta P., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Rawla P., Barsouk A. Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Prz. Gastroenterol. 2019;14:26–38. doi: 10.5114/pg.2018.80001. - DOI - PMC - PubMed

[2] Rawla P., Barsouk A. Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Prz. Gastroenterol. 2019;14:26–38. doi: 10.5114/pg.2018.80001. - DOI - PMC - PubMed

[3] Bernards N., Creemers G.J., Nieuwenhuijzen G.A.P., Bosscha K., Pruijt J.F.M., Lemmens V.E.P.P. No Improvement in Median Survival for Patients with Metastatic Gastric Cancer despite Increased Use of Chemotherapy. Ann. Oncol. 2013;24:3056–3060. doi: 10.1093/annonc/mdt401. - DOI - PubMed

[4] Bernards N., Creemers G.J., Nieuwenhuijzen G.A.P., Bosscha K., Pruijt J.F.M., Lemmens V.E.P.P. No Improvement in Median Survival for Patients with Metastatic Gastric Cancer despite Increased Use of Chemotherapy. Ann. Oncol. 2013;24:3056–3060. doi: 10.1093/annonc/mdt401. - DOI - PubMed

[5] Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed

[6] Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed

[7] Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2022 doi: 10.1016/j.annonc.2022.07.004. - DOI - PubMed

[8] Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2022 doi: 10.1016/j.annonc.2022.07.004. - DOI - PubMed

[9] Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Cooke D., Corvera C., Das P., Enzinger P.C., Enzler T., Fanta P., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. - DOI - PubMed

[10] Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Cooke D., Corvera C., Das P., Enzinger P.C., Enzler T., Fanta P., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Role of ctDNA in Gastric Cancer

Affiliation

The Role of ctDNA in Gastric Cancer

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous